A phase II Trial of Weekly Paclitaxel, 5-Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Breast Cancer

被引：0
|
作者：
David M. Loesch
Lina Asmar
Vikki A. Canfield
Gregory A. Parker
Harry E. Hynes
Peter G. Ellis
William A. Ferri
Nicholas J. Robert
机构：
[1] Oncology and Hematology Associates,
[2] Inc.,undefined
[3] US Oncology,undefined
[4] Cancer Care Associates,undefined
[5] Cancer Care Associates,undefined
[6] Cancer Center of Kansas,undefined
[7] PA,undefined
[8] Oncology Hematology Associates,undefined
[9] Oncology Hematology Associates,undefined
[10] Fairfax-Prince William Hematology-Oncology PC,undefined
来源：
Breast Cancer Research and Treatment | 2003年 / 77卷
关键词：
fluorouracil; leucovorin; metastatic breast cancer; paclitaxel; therapy; weekly;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer.
引用
收藏
页码：115 / 123
页数：8
相关论文
共 50 条
  • [1] A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer
    Loesch, DM
    Asmar, L
    Canfield, VA
    Parker, GA
    Hynes, HE
    Ellis, PG
    Ferri, WA
    Robert, NJ
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 77 (02) : 115 - 123
  • [2] Phase II multicenter trial of a weekly paclitaxel, 5-fluorouracil and leucovorin regimen in patients with metastatic breast cancer
    Loesch, DM
    Robert, NJ
    Keller, AM
    Young, JA
    Rohrbaugh, TM
    Smyth, AC
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 32 - 32
  • [3] Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: Results of a phase II study
    Klaassen, U
    Wilke, H
    Muller, C
    Borquez, D
    Harstrick, A
    Seeber, S
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 58 - 60
  • [4] Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer
    Klaassen, U
    Wilke, H
    Weyhofen, R
    Harstrick, A
    Eberhardt, W
    Muller, C
    Korn, M
    Hanske, M
    Diergarten, K
    Seeber, S
    ANTI-CANCER DRUGS, 1998, 9 (03) : 203 - 207
  • [5] Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: A Vanderbilt cancer center phase II trial
    Nicholson, B
    Paul, D
    Shyr, Y
    Garrett, M
    Hande, KR
    Johnson, DH
    SEMINARS IN ONCOLOGY, 1997, 24 (04) : 20 - 23
  • [6] Phase II Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel as First-Line Therapy for Advanced Gastric Cancer
    Matsubara, Junichi
    Shimada, Yasuhiro
    Kato, Ken
    Nagai, Yushi
    Iwasa, Satoru
    Nakajima, Takako E.
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Takagi, Seiichi
    Kobayashi, Kazuma
    Yoshioka, Akira
    Nakayama, Norisuke
    Tsuji, Akihito
    ONCOLOGY, 2011, 81 (5-6) : 291 - 297
  • [7] Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer
    Blum, Joanne L.
    Dees, E. Claire
    Chacko, Aparna
    Doane, Lisa
    Ethirajan, Sukumar
    Hopkins, Judith
    McMahon, Richard
    Merten, Suzan
    Negron, Angel
    Neubauer, Marcus
    Ilegbodu, Des
    Boehm, Kristi A.
    Asmar, Lina
    O'Shaughnessy, Joyce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4384 - 4390
  • [8] Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer
    Berlin, Jordan
    Posey, James
    Tchekmedyian, Simon
    Hu, Eddie
    Chan, David
    Malik, Imtiaz
    Yang, Liqiang
    Amado, Rafael G.
    Hecht, J. Randolph
    CLINICAL COLORECTAL CANCER, 2007, 6 (06) : 427 - 432
  • [9] A Phase II Study of 5-Fluorouracil/Leucovorin in Combination with Paclitaxel and Oxaliplatin as First-Line Treatment for Patients with Advanced Gastric Cancer
    Lin, Rong-Bo
    Fan, Nan-Feng
    Guo, Zeng-Qing
    Wang, Xiao-Jie
    Liu, Jie
    Chen, Ling
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (06) : 744 - 748
  • [10] Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
    Danso, M. A.
    Blum, J. L.
    Robert, N. J.
    Krekow, L.
    Rotche, R.
    Smith, D. A.
    Richards, P.
    Anderson, T.
    Richards, D. A.
    O'Shaughnessy, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345